FDA‑Approved Tooling Darmiyan’s BrainSee is FDA-approved and already available to physicians, signaling a validated, market-ready product for brain health screening and prognosis that sales teams can position as a trusted diagnostic aid to drive clinical adoption.

Platform Expansion Recent launch of the BrainSee Platform expands the initial FDA-approved test into a broader platform, offering opportunities to upsell additional brain health screening capabilities to existing medical practices and health systems.

Financial Momentum The company has raised significant seed funding and grants with notable investors like Eisai, plus reported annual revenue in the multi‑million range, indicating growing scalability and budget availability for enterprise partnerships and pilot programs.

San Francisco Route Headquartered in San Francisco with a deep tech focus in brain health, Darmiyan is well-positioned to partner with nearby hospitals, academic medical centers, and biotech groups seeking innovative diagnostics and AI-enabled prognostics.

Clinical Integration With physicians as the primary user base and a focus on personalized patient care, sales opportunities exist in integrating BrainSee with electronic health records, imaging workflows, and neurology/heavy cognitive impairment programs to streamline clinical decision support.